Table 2.
Vaccine effectiveness studies in women with prior anogenital disease.
| Author Year | Country | Patient Description | Demonstrated Effect a |
|---|---|---|---|
| Cervical Disease | |||
| Bogani 2020 [24] | Italy | Women undergoing conization for cervical HSIL, 60 months minimum follow-up | 69% in those HPV-free at 6 months to adjust for residual disease. NS in total population. |
| Del Pino 2020 [28] | Spain | Women undergoing conization between January 2013 and July 2018. Mean 22.4 months follow-up | 80% in total population. For those disease-free at 6 months (negative HPV test, negative Pap test, and, if available, a negative biopsy), 100% for HSIL. |
| Ghelardi 2018 [31] | Italy | Women undergoing conization for cervical HSIL/CIN2-3, 36 month median follow-up | 81.2% in analyses adjusting for residual disease. NS without adjustment for residual disease. |
| Kang 2013 [35] | South Korea | Women aged 20–45 years undergoing LEEP for histologically confirmed CIN2-3, 42 month median follow-up, 2 year minimum | 65% in those disease-free at 3 months, b 70% among those with vaccine type lesions before LEEP who were disease-free at 3 months. |
| Petrillo 2020 [43] | Italy | Women undergoing LEEP for CIN1 or greater | 76% for CIN2+. |
| Sand 2020 [44] | Denmark | Women undergoing conization for CIN3 or greater | NS |
| Vulvar Precancer | |||
| Ghelardi 2021 [30] | Italy | Women undergoing surgical treatment for vulvar HSIL | NS overall: 78.5% for disease from incident/reactivated infection. |
| Genital Warts | |||
| Petráš 2015 [42] | Czech Republic | Women aged 16–40 years with prior history of genital warts c | For 4vHPV: 89.0% for certain cases, 74.0% for possible and certain cases. |
HPV, human papillomavirus; NS, not significant. a Reported for multivariable analyses when available. b Women with positive histology of colposcopy-directed biopsy or endocervical curettage 3 months after LEEP are considered to have residual CIN 2-3. c Patients with no prior genital warts were not within the scope of this SLR. Reporting is restricted to women with a prior history of genital warts (N = 175).